This inhibitor of cyclin E (cyclin-dependent kinase 2, Cdk2) activity stops the cell cycle at the G1-S stage, while non-proliferating cells differentiate or undergo apoptosis, which can be interpreted as effects that limit the occurrence and progression of cancer [87]. This evidence concerns the gene CDK2 and cancer.